Firms unite to develop cystic fibrosis drugs in potential $405M deal

09/25/2013 | Reuters · Genetic Engineering & Biotechnology News

AbbVie and Galapagos agreed to collaborate in the development and marketing of novel oral treatments for cystic fibrosis. The partners will build on Galapagos' research and could begin early-stage clinical trials next year. Galapagos will get $45 million upfront and up to $360 million in milestone fees.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care